<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/bcr607.anc" start="13662" end="13668" sStart="13514" offset="148" sid="r11.severe.j.0452" wn="1" wnkey="severe%5:00:00:intense:00" text="HC+ patients had a 3.4-fold elevation in ? LCTX levels, and a 2.2-fold elevation was seen in NC+ patients, indicating that the more severe condition in the HC+ patients is reflected by the ? LCTX marker." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr607.anc" start="7817" end="7828" sStart="null" offset="39" sid="r11.recommend.v.0545" wn="1" wnkey="recommend%2:32:01::" text="The assays were performed as recommended by the manufacturer (Nordic Bioscience Diagnostics, Herlev, Denmark)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr607.anc" start="8650" end="8655" sStart="null" offset="0" sid="null" wn="1" wnkey="powerfulness%1:07:00::" text="The discriminatory &lt;b&gt;power&lt;/b&gt; of the different CTX isoforms or CTX ratios in distinguishing groups from controls was assessed using T or Z scores (i.e." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr607.anc" start="8650" end="8655" sStart="null" offset="0" sid="null" wn="3" wnkey="power%1:09:01::" text="The discriminatory &lt;b&gt;power&lt;/b&gt; of the different CTX isoforms or CTX ratios in distinguishing groups from controls was assessed using T or Z scores (i.e." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr607.anc" start="9744" end="9750" sStart="null" offset="343" sid="r9.level.n.0917" wn="1" wnkey="level%1:07:00::" text="In patients with breast cancer-induced bone metastases, the urinary excretion of the newly synthesised ? LCTX form was more increased than the age-modified forms ? Land ? D. Compared with NC- patients, the HC+ patients had a 3.4-fold elevation in ? LCTX and the NC+ patients had 2.2-fold higher levels of ? LCTX ( P &lt; 0.01)." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr607.anc" start="18903" end="18909" sStart="null" offset="138" sid="r9.level.n.0799" wn="1" wnkey="level%1:07:00::" text="This indicates that the increase in markers is related to metastatic invasion of bone and is reflected in systemic marker levels regardless of the potential antiresorptive effects of antineoplastic therapy." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr607.anc" start="13562" end="13568" sStart="null" offset="48" sid="r9.level.n.0144" wn="2" wnkey="level%1:26:01::" text="HC+ patients had a 3.4-fold elevation in ? LCTX levels, and a 2.2-fold elevation was seen in NC+ patients, indicating that the more severe condition in the HC+ patients is reflected by the ? LCTX marker." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr607.anc" start="16443" end="16449" sStart="null" offset="7" sid="r9.level.n.0146" wn="1" wnkey="level%1:07:00::" text="? LCTX levels alone showed a significant elevation in 58% of the metastatic patients, which probably reflects an increased bone turnover (increased resorption + increased formation) as an important feature in the majority of bone metastatic patients." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/bcr607.anc" start="12632" end="12636" sStart="null" offset="0" sid="null" wn="2147483646" wnkey="null" text="The levels of the three CTX isoforms ? L, ? &lt;b&gt;Land&lt;/b&gt; ? Dwere 2.3-fold to 2.7-fold higher in the postmenopausal women (Table 1), in accordance with previous reports of CTX levels during the menopause [ 15 ] . As all forms were elevated to the same magnitude in postmenopause, the ratios between the newly synthesised ? LCTX form and the older ? &lt;b&gt;Land&lt;/b&gt; ? DCTX forms was not significantly different in premenopausal and postmenopausal women." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/bcr607.anc" start="9254" end="9258" sStart="null" offset="0" sid="null" wn="2147483644" wnkey="null" text="When ratios between the newly synthesised ? Lform and the age-modified forms (? &lt;b&gt;Land&lt;/b&gt; ? D) were calculated, only minor and nonsignificant differences were observed between premenopausal and postmenopausal women." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/bcr607.anc" start="9589" end="9593" sStart="null" offset="0" sid="null" wn="2147483646" wnkey="null" text="In patients with breast cancer-induced bone metastases, the urinary excretion of the newly synthesised ? LCTX form was more increased than the age-modified forms ? &lt;b&gt;Land&lt;/b&gt; ? D. Compared with NC- patients, the HC+ patients had a 3.4-fold elevation in ? LCTX and the NC+ patients had 2.2-fold higher levels of ? LCTX ( P &lt; 0.01)." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/bcr607.anc" start="16737" end="16741" sStart="null" offset="0" sid="null" wn="2147483646" wnkey="null" text="For the ? &lt;b&gt;Land&lt;/b&gt; ? DCTX markers, respectively, 47 and 48% of the metastatic patients had levels 2 SDs above the reference level of nonmetastasised controls (Fig." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/bcr607.anc" start="12632" end="12636" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="The levels of the three CTX isoforms ? L, ? &lt;b&gt;Land&lt;/b&gt; ? Dwere 2.3-fold to 2.7-fold higher in the postmenopausal women (Table 1), in accordance with previous reports of CTX levels during the menopause [ 15 ] . As all forms were elevated to the same magnitude in postmenopause, the ratios between the newly synthesised ? LCTX form and the older ? &lt;b&gt;Land&lt;/b&gt; ? DCTX forms was not significantly different in premenopausal and postmenopausal women." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/bcr607.anc" start="12296" end="12300" sStart="null" offset="0" sid="null" wn="2147483646" wnkey="null" text="The levels of the three CTX isoforms ? L, ? &lt;b&gt;Land&lt;/b&gt; ? Dwere 2.3-fold to 2.7-fold higher in the postmenopausal women (Table 1), in accordance with previous reports of CTX levels during the menopause [ 15 ] . As all forms were elevated to the same magnitude in postmenopause, the ratios between the newly synthesised ? LCTX form and the older ? &lt;b&gt;Land&lt;/b&gt; ? DCTX forms was not significantly different in premenopausal and postmenopausal women." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr607.anc" start="4579" end="4583" sStart="null" offset="475" sid="r10.high.j.0311" wn="1" wnkey="high%3:00:02::" text="The measurement of CTX isoforms, and the ratios between the native ? Lform and the age-modified forms of CTX, indicative of the age of the resorbed collagen fragments, may thus provide clinical useful information for diagnosing and monitoring bone metastasis occurrence in cancer patients [ 11 ] . Such an application of the CTX bone resorption markers may be especially relevant for breast cancer patients, who have a high risk of developing bone metastases." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr607.anc" start="17876" end="17880" sStart="null" offset="0" sid="r10.high.j.0207" wn="1" wnkey="high%3:00:02::" text="High levels of ? LCTX are indicative of an increased bone resorption." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr607.anc" start="12313" end="12317" sStart="null" offset="69" sid="r9.fold.v.0905" wn="2147483645" wnkey="null" text="The levels of the three CTX isoforms ? L, ? Land ? Dwere 2.3-fold to 2.7-fold higher in the postmenopausal women (Table 1), in accordance with previous reports of CTX levels during the menopause [ 15 ] . As all forms were elevated to the same magnitude in postmenopause, the ratios between the newly synthesised ? LCTX form and the older ? Land ? DCTX forms was not significantly different in premenopausal and postmenopausal women." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr607.anc" start="13971" end="13975" sStart="null" offset="15" sid="r9.fold.v.0889" wn="2147483645" wnkey="null" text="5-fold and 1.6-fold compared with NC-patients and with postmenopausal patients, respectively) and in NC+ patients (2." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr607.anc" start="14091" end="14095" sStart="null" offset="2" sid="r9.fold.v.0561" wn="2147483645" wnkey="null" text="2-fold and 2.4-fold compared with NC- patients and with postmenopausal patients)." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr607.anc" start="14104" end="14108" sStart="null" offset="15" sid="r9.fold.v.0959" wn="2147483645" wnkey="null" text="2-fold and 2.4-fold compared with NC- patients and with postmenopausal patients)." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr607.anc" start="9890" end="9894" sStart="null" offset="107" sid="r9.fold.v.0391" wn="2147483645" wnkey="null" text="The levels of ? DCTX, representing the oldest form of CTX, were increased 2.4-fold and 1.7-fold in HC+ patients and in NC+ patients compared with NC- patients (Fig." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr607.anc" start="13588" end="13592" sStart="null" offset="74" sid="r9.fold.v.0532" wn="2147483645" wnkey="null" text="HC+ patients had a 3.4-fold elevation in ? LCTX levels, and a 2.2-fold elevation was seen in NC+ patients, indicating that the more severe condition in the HC+ patients is reflected by the ? LCTX marker." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr607.anc" start="9724" end="9728" sStart="null" offset="323" sid="r9.fold.v.0480" wn="2147483645" wnkey="null" text="In patients with breast cancer-induced bone metastases, the urinary excretion of the newly synthesised ? LCTX form was more increased than the age-modified forms ? Land ? D. Compared with NC- patients, the HC+ patients had a 3.4-fold elevation in ? LCTX and the NC+ patients had 2.2-fold higher levels of ? LCTX ( P &lt; 0.01)." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr607.anc" start="9877" end="9881" sStart="null" offset="94" sid="r9.fold.v.0510" wn="" wnkey="null" text="The levels of ? DCTX, representing the oldest form of CTX, were increased 2.4-fold and 1.7-fold in HC+ patients and in NC+ patients compared with NC- patients (Fig." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr607.anc" start="9128" end="9132" sStart="null" offset="208" sid="r9.fold.v.0338" wn="" wnkey="null" text="The urinary excretion of all CTX forms was significantly higher ( P &lt; 0.001) in the postmenopausal group when compared with the premenopausal women, with approximately 2.5-fold higher levels (Table 1)." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr607.anc" start="12680" end="12689" sStart="null" offset="436" sid="r8.1.different.j.0203" wn="1" wnkey="different%3:00:00::" text="The levels of the three CTX isoforms ? L, ? Land ? Dwere 2.3-fold to 2.7-fold higher in the postmenopausal women (Table 1), in accordance with previous reports of CTX levels during the menopause [ 15 ] . As all forms were elevated to the same magnitude in postmenopause, the ratios between the newly synthesised ? LCTX form and the older ? Land ? DCTX forms was not significantly different in premenopausal and postmenopausal women." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr607.anc" start="16888" end="16896" sStart="null" offset="161" sid="r10.control.n.0449" wn="4" wnkey="control%1:09:02::" text="For the ? Land ? DCTX markers, respectively, 47 and 48% of the metastatic patients had levels 2 SDs above the reference level of nonmetastasised controls (Fig." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr607.anc" start="8865" end="8873" sStart="null" offset="45" sid="r10.control.n.0854" wn="4" wnkey="control%1:09:02::" text="number of SDs from the mean of the controls)." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr607.anc" start="11130" end="11138" sStart="null" offset="126" sid="r9.appear.v.0612" wn="1" wnkey="appear%2:39:00::" text="Although the ? L/? Dratio displayed the highest mean Z score, the urinary excretion of the ? LCTX form still appeared to have the best ability to identify patients affected by bone metastases." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr607.anc" start="6519" end="6526" sStart="null" offset="16" sid="r11.absence.n.0061" wn="1" wnkey="absence%1:26:00::" text="The presence or absence of bone metastasis in patients was determined by bone scintigraphy, and was confirmed by conventional radiography (X-ray) as necessary." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr607.anc" start="6519" end="6526" sStart="null" offset="16" sid="r11.absence.n.0061" wn="1" wnkey="absence%1:26:00::" text="The presence or absence of bone metastasis in patients was determined by bone scintigraphy, and was confirmed by conventional radiography (X-ray) as necessary." />
  </sentences>
</list>